TenNor’s topline results from its Phase 2a rifaquizinone (TNP-2092) provided proof-of-concept of the product’s potential to treat Periprosthetic Joint Infection (PJI) without surgical intervention. Rifaquizinone is a first-in-class, triple-targeting anti-infective addressing implant-associated biofilm infections.